Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of EUR 113.18 billion. The enterprise value is 128.22 billion.
Market Cap | 113.18B |
Enterprise Value | 128.22B |
Important Dates
The last earnings date was Thursday, April 24, 2025.
Earnings Date | Apr 24, 2025 |
Ex-Dividend Date | Mar 14, 2025 |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.28% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 20.51.
PE Ratio | 20.51 |
Forward PE | n/a |
PS Ratio | 4.26 |
PB Ratio | 6.41 |
P/TBV Ratio | n/a |
P/FCF Ratio | 12.43 |
P/OCF Ratio | 11.80 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.60, with an EV/FCF ratio of 14.08.
EV / Earnings | 23.23 |
EV / Sales | 5.07 |
EV / EBITDA | 10.60 |
EV / EBIT | 13.47 |
EV / FCF | 14.08 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 1.31.
Current Ratio | 1.30 |
Quick Ratio | 1.00 |
Debt / Equity | 1.31 |
Debt / EBITDA | 1.82 |
Debt / FCF | 2.54 |
Interest Coverage | 11.01 |
Financial Efficiency
Return on equity (ROE) is 32.66% and return on invested capital (ROIC) is 15.59%.
Return on Equity (ROE) | 32.66% |
Return on Assets (ROA) | 12.00% |
Return on Invested Capital (ROIC) | 15.59% |
Return on Capital Employed (ROCE) | 24.54% |
Revenue Per Employee | 1.51M |
Profits Per Employee | 313,569 |
Employee Count | 17,600 |
Asset Turnover | 0.51 |
Inventory Turnover | 2.22 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.90% in the last 52 weeks. The beta is 0.34, so Gilead Sciences's price volatility has been lower than the market average.
Beta (5Y) | 0.34 |
52-Week Price Change | +44.90% |
50-Day Moving Average | 100.88 |
200-Day Moving Average | 85.37 |
Relative Strength Index (RSI) | 35.75 |
Average Volume (20 Days) | 3,845 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 2.11 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of EUR 26.59 billion and earned 5.52 billion in profits. Earnings per share was 4.38.
Revenue | 26.59B |
Gross Profit | 20.81B |
Operating Income | 10.01B |
Pretax Income | 6.31B |
Net Income | 5.52B |
EBITDA | 12.57B |
EBIT | 10.01B |
Earnings Per Share (EPS) | 4.38 |
Balance Sheet
The company has 7.33 billion in cash and 23.14 billion in debt, giving a net cash position of -15.81 billion.
Cash & Cash Equivalents | 7.33B |
Total Debt | 23.14B |
Net Cash | -15.81B |
Net Cash Per Share | n/a |
Equity (Book Value) | 17.65B |
Book Value Per Share | 14.18 |
Working Capital | 3.47B |
Cash Flow
In the last 12 months, operating cash flow was 9.59 billion and capital expenditures -482.95 million, giving a free cash flow of 9.11 billion.
Operating Cash Flow | 9.59B |
Capital Expenditures | -482.95M |
Free Cash Flow | 9.11B |
FCF Per Share | n/a |
Margins
Gross margin is 78.29%, with operating and profit margins of 37.65% and 20.76%.
Gross Margin | 78.29% |
Operating Margin | 37.65% |
Pretax Margin | 23.75% |
Profit Margin | 20.76% |
EBITDA Margin | 47.28% |
EBIT Margin | 37.65% |
FCF Margin | 34.26% |
Dividends & Yields
This stock pays an annual dividend of 2.87, which amounts to a dividend yield of 3.18%.
Dividend Per Share | 2.87 |
Dividend Yield | 3.18% |
Dividend Growth (YoY) | 2.99% |
Years of Dividend Growth | 10 |
Payout Ratio | 82.45% |
Buyback Yield | -0.28% |
Shareholder Yield | 2.90% |
Earnings Yield | 4.88% |
FCF Yield | 8.05% |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.
Last Split Date | Jan 28, 2013 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |